Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RITUXIMAB Cause Intensive care unit acquired weakness? 36 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 36 reports of Intensive care unit acquired weakness have been filed in association with RITUXIMAB (Rituxan). This represents 0.0% of all adverse event reports for RITUXIMAB.

36
Reports of Intensive care unit acquired weakness with RITUXIMAB
0.0%
of all RITUXIMAB reports
1
Deaths
36
Hospitalizations

How Dangerous Is Intensive care unit acquired weakness From RITUXIMAB?

Of the 36 reports, 1 (2.8%) resulted in death, 36 (100.0%) required hospitalization, and 1 (2.8%) were considered life-threatening.

Is Intensive care unit acquired weakness Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RITUXIMAB. However, 36 reports have been filed with the FAERS database.

What Other Side Effects Does RITUXIMAB Cause?

Off label use (39,751) Drug ineffective (32,186) Rheumatoid arthritis (19,850) Pain (16,675) Fatigue (15,602) Arthralgia (12,529) Rash (12,102) Drug intolerance (11,876) Infusion related reaction (11,871) Joint swelling (11,170)

What Other Drugs Cause Intensive care unit acquired weakness?

METHYLPREDNISOLONE (57) PROPOFOL (55) MIDAZOLAM (49) PREDNISOLONE (47) PREDNISONE (45) MYCOPHENOLATE MOFETIL (42) THIOPENTAL (41) FENTANYL (40) LEVETIRACETAM (40) VANCOMYCIN (37)

Which RITUXIMAB Alternatives Have Lower Intensive care unit acquired weakness Risk?

RITUXIMAB vs RITUXIMAB-ABBS RITUXIMAB vs RITUXIMAB-ARRX RITUXIMAB vs RITUXIMAB-PVVR RITUXIMAB vs RIVAROXABAN RITUXIMAB vs RIVASTIGMINE

Related Pages

RITUXIMAB Full Profile All Intensive care unit acquired weakness Reports All Drugs Causing Intensive care unit acquired weakness RITUXIMAB Demographics